{
    "nctId": "NCT00692289",
    "briefTitle": "Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer",
    "officialTitle": "Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1510,
    "primaryOutcomeMeasure": "Elements of the investigator questionnaire SF RAND-36 questionnaire",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of informed consent\n* Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex\n* Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment.\n\nExclusion Criteria:\n\n* Allergy to substance of medication\n* Pre-perimenopausal woman\n* Woman not eligible for treatment",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}